EQQIL

Equillium is a Nasdaq-listed clinical-stage biotechnology company based in La Jolla, California, focused on immunology and inflammation. The company is currently prioritizing EQ504, a potent and selective aryl hydrocarbon receptor modulator being developed initially for ulcerative colitis and other gastrointestinal diseases, with potential expansion into inflammatory lung disease. Equillium also maintains EQ302, an orally delivered bi-specific cytokine inhibitor targeting interleukin-15 and interleukin-21 for gastrointestinal indications including celiac disease. Historically, the company advanced itolizumab and other multi-cytokine inhibitor programs in autoimmune and inflammatory diseases, but recent corporate disclosures indicate EQ504 is the primary actively advancing product candidate. The company combines targeted immunomodulation with platform capabilities in composite peptide design for multi-cytokine blockade.